+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Plasma Protein Therapeutics Market - Growth, Trends, COVID-19 Impact, and Forecast (2022 - 2027)

  • ID: 4896089
  • Report
  • June 2022
  • Region: Global
  • 115 Pages
  • Mordor Intelligence
The plasma protein therapeutics market studied has been projected to register a CAGR of nearly 5.3% over the forecast period (2022-2027).

The COVID-19 pandemic is expected to have a significant impact on the global market. The current COVID-19 pandemic has also temporarily impacted plasma donation globally, affecting the plasma protein therapeutics market. However, researchers are focusing on plasma-based therapeutics to identify whether these therapies have any promising role in treating the COVID-19 virus. For instance, in April 2020, Kamada Ltd. and Kedrion Biopharma, two biopharmaceutical companies specialized in plasma-derived protein therapeutics, entered a global collaboration for the development, manufacturing, and distribution of a human plasma-derived Anti-SARS-CoV-2 (COVID-19) polyclonal immunoglobulin (IgG) product as a potential treatment for COVID-19 patients. In addition, in April 2020, the Indian Council of Medical Research (ICMR) pursued the participation of researchers for conducting a clinical trial of convalescent plasma therapy to treat critically ill COVID-19 patients and floatespecializingl for it. Again, in May 2020, BioAegis Therapeutics started researching its lead product, recombinant human plasma gelsolin therapy (rhu-pGSN), believing it as a viable therapeutic option for patients suffering from severe lung injury due to COVID-19. Thus, Covid-19 is anticipated to have a positive impact on the studied market. Moreover, the increase in the usage of therapeutic protein drugs in the treatment of a wide range of clinical symptoms is projected to generate unique growth opportunities for this market in the coming years.

Additionally, the major factors that are leading to the growth of the market include the increasing prevalence of autoimmune disorders, immune deficiency disorders, neurological and bleeding disorders. Along with these factors, the rise in the geriatric population across the globe is a major reason for market growth as elderly people are more prone to neurological disorders.

Furthermore, the growing investments in research and development programs by biotechnology and pharmaceutical companies are boosting the market growth. For instance, in November 2021, Biognosys launched the Next-Generation blood biomarker discovery solution. The improved service offer unprecedented depth, precision, and throughput, quantifying up to 3,000 proteins in plasma or serum. Additionally, the increasing geriatric population worldwide increasing the patient pool as the elderly are more prone to neurological diseases. Furthermore, beneficial government initiatives, escalating awareness levels among the blood donors, the existence of advanced protein fractioning procedures, greater per capita income in developed countries, and an increase in the number of research partnerships are some of the drivers expected to increase market growth the region.

Therefore, owing to the aforementioned factors the studied market is predicted to see growth over the forecast period. However, the stringent regulations for the handling of plasma protein products and the lack of proper reimbursement policies are the major drawbacks that are expected to hinder the market growth.

Key Market Trends

Hemophilia Segment is Expected to be Fastest-growing over the Forecast Period

Hemophilia is a unique bleeding disorder of genetic origin that prevents the normal clotting of blood. The major symptom of this disorder is uncontrolled and often causes spontaneous bleeding in different areas of the body. The amount of bleeding depends on the severity of hemophilia. Owing to the increasing number of patients identified with hemophilia, the segment is expected see growth in future.

The World Federation of Hemophilia 2020 Data report shows that the most common reason for hospitalization was joint bleed for both hemophilia A (70%) and hemophilia B patients (60%). Additionally, as per the Global Hemophilia Care 2019 report, more than 1,125,000 men worldwide have an inherited bleeding disorder, and 418,000 of those have a severe version of the most undiagnosed disease. This prevalence of hemophilia among target population is increasing the demand for advanced plasma protein therapeutics. As fresh frozen plasma (FFP) is one of the most commonly available for treatment of hemophilia A and B in some countries, this is expected to drive growth of the hemophilia segment.

Hemophilia A is the most prevalent type of the condition, with an incidence rate of 1 in 4,000 to 1 in 5,000 males worldwide born with this disorder and Hemophilia B occurs in approximately 1 in 20,000 newborn males across the world shows the article published in MedlinePlus, National Library of Medicine (NLM) in May 2022. The increasing prevalence of hemophilia and the huge patient pool are expected to trigger market growth during the forecast period.

Moreover, the increasing research and development (R&D) of new therapeutics and company activities are expected to boost the segment growth over the forecast period. For instance, in July 2021, Sanofi presented Clinical data and new research from Sanofi’s rare blood disorders portfolio of marketed and investigational therapies for people with hemophilia, immune thrombocytopenia (ITP) and acquired thrombotic thrombocytopenic purpura (aTTP) at the at the International Society on Thrombosis and Haemostasis (ISTH) 2021 Virtual Congress. In addition, in December 2021, Pfizer Inc. and Sangamo Therapeutics, Inc., a genomic medicines company, announced updated follow-up data from the Phase 1/2 Alta study of giroctocogene fitelparvovec, an investigational gene therapy for patients with moderately severe to severe hemophilia A. Thus, increasing product development in the segment is anticipated to drive the market growth over the forecast period.

Hence, hemophilia by application segment is growing and it is expected to have a significant growth over the forecast period. Hence, driving the growth of the studied market.

North America is Expected to Dominate the Market Over the Forecast Period

North America is expected to dominate the overall plasma protein therapeutics market throughout the forecast period. The market growth is due to factors like the increasing prevalence and incidence of autoimmune and neurological diseases. The United States is expected to be the largest market in this region.

The well-established healthcare infrastructure-focused market players on R&D for plasma protein therapeutics, coupled with recent product launches and the rising burden of autoimmune disorders, are primary growth factors for the market in the United States. The Centers for Disease Control and Prevention (CDC) data updated in September 2020 shows that Hemophilia A affects 1 in 5,000 male births and about 400 babies are born with hemophilia A each year.​ As per CDC, about 70% of people with hemophilia in the United States receive multidisciplinary, comprehensive care in a network of federally funded hemophilia treatment centers. This prevalence of hemophilia A in the country is demanding the development of advanced plasma protein therapeutics in the country, propelling the market growth in the region.

Additionally, according to the United States Arthritis Foundation 2019 report, arthritis is the leading cause of disability among adults. By conservative estimates, the number of adults in the United States with doctor-diagnosed arthritis is projected to increase 49 percent to 78.4 million (25.9% of all adults) by 2040. As the Platelet-rich plasma therapy or PRP therapy or autologous conditioned plasma (ACP) therapy, attempts to take advantage of the blood's natural healing properties to repair damaged cartilage, tendons, ligaments, muscles, or even bone. The therapy is currently used to treat arthritis. Hence, as per the estimates mentioned above, the growing arthritis cases in the United States is anticipated to create opportunity for advanced plasma protein therapies, driving the overall market growth in the country.

Furthermore, there has been an increased focus on convalescent plasma therapy to treat COVID-19 in the United States. In April 2020, Johns Hopkins received the Food and Drug Administration (FDA) approval to test blood plasma therapy to treat COVID-19 patients. And FDA also issued a guidance to provide recommendations for investigational convalescent plasma therapy. Thus, the market for plasma protein therapeutics is projected to experience significant growth in the United States.

Therefore, owing to the aforementioned factors the North America region is expected to witness a strong growth over the forecast period driving the growth of the studied market.

Competitive Landscape

In the current scenario, the strategies by the market players are increasing and it's fueling the global plasma protein therapeutics market. The market is competitive in nature due to heavy demand of products. The plasma protein therapeutics market is moderately competitive and consists of several major players. The market is competitive in nature. Some companies currently dominating the market are Takeda Pharmaceutical Company Limited, Octapharma USA Inc., Biotest UK, Baxter, Grifols, S.A., and CSL, among others.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

This product will be delivered within 2 business days.

Table of Contents

1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Incidence of Autoimmune and Neurological Diseases
4.2.2 Rise in Research and Development in the Plasma Protein
4.3 Market Restraints
4.3.1 Strict Regulations for the Handling of Plasma Protein Products
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION (Market Size by Value - USD million)
5.1 By Product
5.1.1 Immunoglobulin
5.1.2 Albumin
5.1.3 Plasma Derived Factor Viii
5.1.4 Other Products
5.2 By Application
5.2.1 Hemophilia
5.2.2 Idiopathic Thrombocytopenic Purpura
5.2.3 Primary Immunodeficiencies
5.2.4 Other Applications
5.3 Geography
5.3.1 North America United States Canada Mexico
5.3.2 Europe Germany United Kingdom France Italy Spain Rest of Europe
5.3.3 Asia-Pacific China Japan India Australia South Korea Rest of Asia-Pacific
5.3.4 Middle-East and Africa GCC South Africa Rest of Middle-East and Africa
5.3.5 South America Brazil Argentina Rest of South America
6.1 Company Profiles
6.1.1 Takeda Pharmaceutical Company Limited
6.1.2 Octapharma USA Inc.
6.1.3 Grifols, S.A.
6.1.4 CSL
6.1.5 Biotest UK
6.1.6 Baxter
6.1.7 China Biologic Products Holdings, Inc.
6.1.8 Kedrion S.p.A
6.1.9 Bio Products Laboratory Ltd.
6.1.10 ADMA Biologics, Inc.
6.1.11 Arthrex, Inc.
6.1.12 Johnson and Johnson (SePuy Synthes)

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Takeda Pharmaceutical Company Limited
  • Octapharma USA Inc.
  • Grifols, S.A.
  • CSL
  • Biotest UK
  • Baxter
  • China Biologic Products Holdings, Inc.
  • Kedrion S.p.A
  • Bio Products Laboratory Ltd.
  • ADMA Biologics, Inc.
  • Arthrex, Inc.
  • Johnson and Johnson (SePuy Synthes)